EN DE
Watch USA Equities Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

USA Equities Corp (USAQ) fair value: what the stock is really worth

As of Nov 3, 2026: fair value (intrinsic value) of USA Equities Corp stock $0.45, price $0.32, upside +39.5%, quality 64 out of 100. Rating: undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

UE USA Equities Corp logo Thin data Nov 7, 2026

USA Equities Corp

USAQ · US
Meets all rules

The stock costs 28% less than our calculation considers fair.

Fair value $0.4505 · Undervalued
Quality 64/100
Solidly profitable · 17.4% net margin (TTM)
Low debt
Ranks above peers (8/13)
Revenue last quarter +40% vs. a year ago.
Mixed Growth (revenue 5y +84.9 %/yr in USD)
Wide moat 69/100 · thin data
Negative free cash flow over the last twelve months
Thin data
⚠ Dilution⚠ Thinly traded
Watch USA Equities Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.9200 $0.0160 Fair Value $0.4505 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.0160 – $0.9200 · fair‑value band $0.2720 – $0.7480 · the $0.3230 price screens below the $0.4505 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow USA Equities in your weekly email

Every Wednesday you see whether USA Equities is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures.

Show moreShow less

The company focuses on value-based healthcare, informatics, and algorithmic personalized medicine, including digital therapeutics, behavior based remote patient monitoring, and chronic care and preventive medicine.

Its digital healthcare and clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, address chronic care, and preventive medicine.

The company provides quality health system lab expert system (QHSLab), designed to function as an extension of a medical practice's existing clinical workflow that supports structured screening, automated documentation, and digital follow-up while minimizing disruption to physicians and staff; and AllergiEnd, a diagnostic and allergen immunotherapy system for the busy non-allergist in a primary care setting.

Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. The company was incorporated in 1983 and is based in West Palm Beach, Florida.

Stock analysis

USA Equities Corp (USAQ) currently trades at $0.3230, while our model-based Fair Value estimate is $0.4505, implying the stock looks roughly 28% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $0.8500 per share, and 14 of the 23 models we run sit above the $0.3230 price.

Bear case: the Multiples group reads lowest at $0.1000, and 9 of the 23 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.2720 (bear) to $0.7480 (bull), the price of $0.3230 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

USA Equities Corp reported revenue of $2.7M in FY2025 versus $1.4M in FY2021, a compound +17.5%/yr. Reported net income was $457K in FY2025.

Key figures

Market cap $4.9M Micro · P/E ratio 10.8 · P/S ratio 1.61 · EPS (TTM) $0.0300 · Net margin 17.4% · Return on equity 115% · Return on assets (EBIT) −9.6% (5-year average) · Operating margin 5.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 69 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 97% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 39%, USAQ screens cheaper than that median.

Fair Value models

Bear $0.2720 Fair Value $0.4505 Bull $0.7480
Price $0.3230 · Upside +39.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.0257 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $0.4500 $0.7400 $1.57 75
EPV $0.1100 $0.1200 $0.1400 74
Growth DCF $0.4300 $0.8200 $1.57 74
All 23 models by family
DCF Models
FCF DCF $0.4500 $0.7400 $1.57 75
5Y Revenue Exit $0.2100 $0.3100 $0.4900 72
5Y EBITDA Exit $0.2600 $0.4200 $0.6900 73
5Y P/E Exit $0.5100 $1.03 $1.71 68
10Y Revenue Exit $0.2800 $0.4300 $0.5900 67
10Y EBITDA Exit $0.3200 $0.5300 $0.8800 66
10Y P/E Exit $0.4900 $1.00 $1.87 60
Earnings-Based
Graham-Dodd $0.2100 $1.44 $2.02 63
Lynch FV $0.4300 $0.6100 $0.8000 61
PEG = 1.0 $0.4300 $0.6100 $0.8000 57
EPV $0.1100 $0.1200 $0.1400 74
Multiples
P/E Multiple $0.5000 $0.6700 $0.8400 63
P/S Multiple $0.3900 $0.5200 $0.6500 58
P/B Multiple $0.0800 $0.1000 $0.1300 55
EV/EBIT $0.0100 $0.0400 $0.0800 58
EV/EBITDA $0.0500 $0.1000 $0.1500 64
EV/Revenue n/a $0.0100 $0.0400 50
Asset-Based
NCAV (Graham) $0.0100 $0.0200 $0.0300 52
Growth DCF
Growth DCF $0.4300 $0.8200 $1.57 74
Rev-Margin DCF $0.2100 $0.3300 $0.5000 72
Economic Profit
Residual Income $0.2000 $0.2900 $0.6600 64
ROIC Compounder $0.1200 $0.1500 $0.1800 72
Growth Earnings
Growth-Adj P/E $0.6000 $0.8500 $1.11 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 64/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 92
How much profit the company makes from its sales and capital
Quality Growth 93
Are margins and returns getting better?
Cashflow 43
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 61
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 47
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 61
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+26.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.9%
Start year 2020 (pandemic)
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−220.9% (2020) → 4.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.0% a year for the price.

Watch USAQ, get fair value alerts →

Compare USA Equities Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 64 · Above median
Fair Value upside +39.5% · Top 25%
Profitability
Return on equity (12 months) 114.6% · Top 25%
Return on assets 21.1% · Top 25%
Net margin (12 months) 17.4% · Top 25%
Operating margin (12 months) 5.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 40.0% · Top 25%
Balance sheet
Debt / equity 0.06× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 10.8× · Cheapest 25%
P/B 2.99× · Pricier than median
P/S (12 months) 1.61× · Cheaper than median
Price / free cash flow (fiscal year) 27.3× · Pricier than median
EV/EBITDA 27.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)86 · sector 6
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)100 · sector 17
HEALTH (low debt)97 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs USAQ
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs USAQ
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs USAQ
DexCom, Inc DXCM $79.41 $87.35 +10% vs USAQ
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs USAQ
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs USAQ
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs USAQ
Abbott Laboratories, ABT $109.93 $75.28 −32% vs USAQ
Medtronic plc MDT $101.80 $65.61 −36% vs USAQ
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs USAQ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

USA Equities Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "USA Equities Corp Fair Value". https://www.fairvalue-calculator.com/stock/USAQ

Frequently asked questions

Is USA Equities Corp (USAQ) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.4505 versus a price of $0.3230, about +39% upside (undervalued).
What is the fair value of USAQ?
Our model-based fair value for USA Equities Corp is $0.4505 (as of Nov 7, 2026), built from audited fundamentals. The current price: $0.3230.
What is the quality score of USAQ?
USA Equities Corp has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for USA Equities Corp (USAQ)?
Our model-based price target is the fair value of $0.4505 (as of Nov 7, 2026) from 23 valuation models. Cautious scenario $0.2720, optimistic scenario $0.7480. It is a calculation from audited fundamentals, not an analyst target.
What is the USA Equities Corp stock forecast for 2026?
Our models put fair value at $0.4505, about +39% upside versus a price of $0.3230 (undervalued). Cautious scenario $0.2720, optimistic scenario $0.7480. The calculation is refreshed regularly with new filings.
What is the revenue of USA Equities Corp (USAQ)?
USA Equities Corp reported trailing-twelve-month revenue of about $3.0M (latest available figure, as of Nov 7, 2026).
What growth is priced into USA Equities Corp (USAQ)?
For today's price to be fair in a discounted-cash-flow model, USA Equities Corp would have to grow free cash flow by +13.7 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +84.9 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of USAQ use?
Our models discount USA Equities Corp at 8.9 %: a base by market capitalisation (nano), damped by beta 0.65, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For USA Equities Corp that is +13.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has USA Equities Corp (USAQ) delivered so far?
Over the past 5 years revenue at USA Equities Corp grew +84.9 % a year. The price currently implies free-cash-flow growth of +13.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of USA Equities Corp (USAQ) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into USA Equities Corp (+13.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of USA Equities Corp (USAQ)?
The free-cash-flow yield on the price is 3.67 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow USA Equities Corp produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of USA Equities Corp (USAQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For USA Equities Corp it is $0.4505 per share (as of Nov 7, 2026), against a price of $0.3230. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is USA Equities Corp stock overvalued or undervalued in 2026?
As of Nov 7, 2026, USAQ trades below its calculated fair value: price $0.3230, fair value $0.4505, a gap of about +39% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of USAQ?
No. The price is what the market pays today ($0.3230); the fair value is what the company's own numbers justify ($0.4505). For USA Equities Corp the two are $0.1275 per share apart. That gap is exactly why we show both numbers side by side.
How much is USA Equities Corp worth?
The market values USA Equities Corp at about $4.9M (market capitalisation, as of Nov 7, 2026). Per share that is $0.3230; our models calculate a fair value of $0.4505 per share.
What do the bullish and bearish scenarios say about USAQ?
Our models span a range for USA Equities Corp: cautious scenario $0.2720, base $0.4505, optimistic $0.7480 per share (as of Nov 7, 2026, price $0.3230). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of USAQ?
USA Equities Corp trades at a price-to-earnings ratio of 10.8 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.4505 is built from several models across several years. Other multiples: P/B 3.0, P/S 1.6, EV/EBITDA 27.9.
How solid is the balance sheet of USA Equities Corp (USAQ)?
Balance-sheet figures for USA Equities Corp (as of Nov 7, 2026): return on equity 114.6%, debt of 0.06 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is USAQ from its 52-week high?
USA Equities Corp trades at $0.3230, about 65% below its 52-week high of $0.9200 and 97% above the low of $0.1640 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4505 is for.
Which stocks are comparable to USA Equities Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is USA Equities Corp stock attractive at the current price?
The data as of Nov 7, 2026: price $0.3230, calculated fair value $0.4505 (+39%), Quality Score 64/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of USAQ calculated?
We run USA Equities Corp through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.4505 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. USA Equities Corp currently trades 28% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of USA Equities Corp (USAQ)?
The closing price on Nov 3, 2026 was $0.3230. Our model-based fair value is $0.4505, about +39% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with USA Equities Corp right now?
The model range is unusually wide ($0.2720 to $0.7480). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of USA Equities Corp

How large is the market capitalisation of USA Equities Corp (USAQ)?
The market capitalisation of USA Equities Corp is $4.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of USA Equities Corp (USAQ)?
The price-to-sales ratio of USA Equities Corp is 1.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of USA Equities Corp (USAQ)?
Earnings per share at USA Equities Corp are $0.0300 (price ÷ EPS = P/E 10.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of USA Equities Corp (USAQ)?
The net margin of USA Equities Corp is 17.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of USA Equities Corp (USAQ)?
The return on equity (ROE) of USA Equities Corp is 115% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of USA Equities Corp (USAQ)?
On an EBIT basis the return on assets of USA Equities Corp is −9.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of USA Equities Corp (USAQ)?
The operating margin of USA Equities Corp is 5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at USA Equities Corp (USAQ)?
Revenue at USA Equities Corp is growing +40.0% versus a year earlier (3y avg +29.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at USA Equities Corp (USAQ)?
Earnings per share at USA Equities Corp are growing −35.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does USA Equities Corp (USAQ) carry?
The net debt of USA Equities Corp is $1.6M (fiscal year 2024, ≈ 8.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch USA Equities Corp in the live analysis

One click puts USA Equities Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.